…RAP (5.8% vs 10.5%; RR 0.554, 95% CI 0.487–0.631, p<0.001), and pancreatic cancer (2.0% vs 3.9%; RR 0.498, 95% CI 0.421–0.590, p<0.001). ED visit…
RAP
This disease is selected. Its supporting articles are shown below.
Articles mentioning RAP
5 articles · page 1 of 1… placebo; OR 0.76, 95% CI 0.27 to 2.12; p=0.60). Development of diabetes mellitus was more frequent in the simvastatin group (4 vs 0 patients; OR…
… structural damage, lifelong metabolic and functional sequelae, pancreatic cancer risk and poor quality of life. Against this backdrop, the repur…
….43 to 2.66; p=0.88), with no difference in time to recurrence. New-onset diabetes occurred in four participants receiving simvastatin, raising sa…
…placebo in patients with recurrent acute pancreatitis (RAP) and chronic pancreatitis (CP) in reducing the recurrence of pancreatitis. Statins have p…